This application of the Comprehensive Cancer Center of Wake Forest University (CCCWFU) requests renewal of its Cancer Center Support Grant for Years 33 through 37. During the current grant period, peer-reviewed annual direct cancer funding increased from $10.8 to $25.4 million, NCI funding increased from $5.1 to $12 million, and annual direct funding per member increased from $106,000 to $233,000. Interprogrammatic publications increased from 9.1% to 11.8%, intraprogrammatic publications increased from 16.7% to 28.6%, and interdepartmental publications increased from 17.4% to 28.7%. Formal collaboration (co-investigators, consultants, or collaborators) with other Cancer Center members is present on 68.5% of peer-reviewed research grants listed in summary II. In the current grant cycle we have made few structural changes, and instead focused on the execution of our scientific vision. Support is requested for four Programs: Cell Growth and Survival, DNA Damage and Cellular Defense, Clinical Research and Cancer Control as well as seven shared resources: Biomolecular Resource Laboratory, Cell Culture and Viral Vector, Microarray, Cellular Imaging, Tumor Tissue, Biostatistics, and Clinical Research Management. During this funding period, the CCCWFU opened a new 225,000 sq.ft. outpatient cancer center, and continued its longstanding focus and unique contributions to the cancer problems in our 7 state catchment area. The blueprint for our next five years is embodied in this application, which provides the Center's vision of how it can reduce the burden of cancer in our region and in the nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA012197-34S1
Application #
7879819
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-02-01
Project End
2012-01-31
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
34
Fiscal Year
2009
Total Cost
$100,001
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Su, Weijun; Hong, Lixin; Xu, Xin et al. (2018) miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. Oncogene 37:5618-5632
Miller Jr, David P; Denizard-Thompson, Nancy; Weaver, Kathryn E et al. (2018) Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Ann Intern Med 168:550-557
Rimkus, Tadas K; Carpenter, Richard L; Sirkisoon, Sherona et al. (2018) Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res 78:2589-2600
Bonin, Keith; Smelser, Amanda; Moreno, Naike Salvador et al. (2018) Structured illumination to spatially map chromatin motions. J Biomed Opt 23:1-8
Rogers, LeAnn C; Davis, Ryan R; Said, Naveen et al. (2018) Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy. Redox Biol 15:380-386
Maggiore, Ronald J; Callahan, Kathryn E; Tooze, Janet A et al. (2018) Geriatrics fellowship training and the role of geriatricians in older adult cancer care: A survey of geriatrics fellowship directors. Gerontol Geriatr Educ 39:170-182
Melvin, Ryan L; Xiao, Jiajie; Godwin, Ryan C et al. (2018) Visualizing correlated motion with HDBSCAN clustering. Protein Sci 27:62-75
Faig, Jennifer; Haughton, Michael; Taylor, Richard C et al. (2018) Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy. Am J Clin Oncol 41:432-440
Nelson, Kimberly J; Perkins, Arden; Van Swearingen, Amanda E D et al. (2018) Experimentally Dissecting the Origins of Peroxiredoxin Catalysis. Antioxid Redox Signal 28:521-536
Swanner, Jessica; Singh, Ravi (2018) Synthesis, Purification, Characterization, and Imaging of Cy3-Functionalized Fluorescent Silver Nanoparticles in 2D and 3D Tumor Models. Methods Mol Biol 1790:209-218

Showing the most recent 10 out of 548 publications